Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
Volume
5.01 M
Value Traded
235.48 M
Short % Float
8.75%
Days to Cover
1.3
0%Week
0%1 Month
0%3 Month
0%6 Month
0%5 Year
+91.8%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
3.54 B
EPS (TTM)
-3.41
P/E Ratio
-
Ent. Value
3.26 B
Total Shares
75.35 M
Float Shares
72.94 M
Insiders
3.19%
Institutions
97.88%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
SWTX Catalyst Timeline
Dated clinical, regulatory and corporate events for SpringWorks Therapeutics, Inc.
Past FDA Catalysts and PDUFA Decisions
How SWTX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-12-31 | SW-3431 | IND Submission | IND |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SW-682 Small moleculeNCT06251310 | Advanced Solid Tumor | Phase 1 | RECRUITING | 186 | Jan 18, 2027 | ||||||
| Nirogacestat Small moleculeMarketedNCT07170644 | Desmoid Tumor | Approved | ACTIVE NOT_RECRUITING | 190 | Oct 9, 2029 | ||||||
| Mirdametinib Small moleculeMarketedNCT03962543 | Plexiform Neurofibroma | Approved | ACTIVE NOT_RECRUITING | 114 | Dec 22, 2028 | ||||||
| Nirogacestat Small moleculeMarketedNCT05879146 | Tumor | Approved | RECRUITING | 40 | Jan 31, 2028 | ||||||
| Mirdametinib Small moleculeMarketedNCT06159166 | NF1 | Approved | RECRUITING | 24 | Nov 15, 2028 | ||||||
| Nirogacestat Small moleculeNot countedNCT05348356 | Ovarian Granulosa-Stromal Tumor | Phase 2 | COMPLETED | 53 | Jul 14, 2025 |
Clinical Trial Results
Readouts, endpoints and source filings for every SWTX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| OGSIVEO | desmoid tumors | Phase 3 | 2025-10-21 | 34.3% (n = 24) in year 1; 45.7% (n = 32) in patients who received OGSIVEO for up to 4 years; 24 (34.3%) PRs and 8 (11.4%) CRs in total; −32.3% at year one (n=46); −75.8% (n=15) for patients completing at least four years of treatmentRead More | SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical OncologyRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Edris BadreddinOfficer (Chief Operating Officer) | Sell | -3,924 185,788 held | $53.12 | 03/03/2025 |
Hedge Fund 13F Activity
Hedge Funds invested in SWTX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 0.2 % | 3.49 M | 74.27 K |
Ownership Trends
SWTX Short Interest
Shares sold short, counted twice a month.
8.75%
Short % of Float
of tradable shares sold short
6.9M
Shares Sold Short
+8.5% vs prior count
1.3 Low
Days to Cover
trading days of normal volume to buy every short share back
5.2M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How SWTX ranks across every disease it competes in
Competitive Position is a premium feature
See how SWTX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialSWTX News
About SpringWorks Therapeutics, Inc.
Founded13-09-2019
BIOPHARMAWATCH ELITE PLUS
Trade the next SWTX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime